| Revenue growth | 19% YoY for FY26; 18% YoY for Q4 FY26. |
|---|---|
| Margins | Adjusted EBITDA margin improved from 12.7% to 13.4% in FY26. |
| Demand visibility | Strong growth in Chronic (53%) and Complex Generic (74%) portfolios. |
| Management confidence | High; citing 13 consecutive quarters of record revenue. |
Growth
Revenue grew 19% YoY to ₹904 Cr; Adjusted PAT increased 31% YoY to ₹83 Cr in FY26.
Outlook
Plant-6 OSD facility mechanical completion achieved; commercialization targeted for H1 FY27. Proposed dividend of ₹13 Cr.
Risks
Moderate industry volume growth (2.7% in IPM); lead times associated with export market regulatory approvals.
Earnings Call filed with NSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,028.00
- Market cap
- ₹2,158 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 32.5×Sector 47.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Results Update
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, an 18% YoY growth. The release highlights an adjusted EBITDA of Rs 34 crore and PAT of Rs 25 crore.
Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Board Meeting Date
Windlas Biotech Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone financial results for the quarter ending June 30, 2026.
Windlas Biotech Annual General Meeting
Windlas Biotech Ltd held its 25th Annual General Meeting on July 23, 2026. Shareholders approved the financial statements and a final dividend of Rs. 6.30 per share.